Humoral and T-cell response to SARS-CoV-2 vaccination in patients with rheumatoid arthritis.
Carolina Ayelen IsnardiMargarita LandiLeonel CrucesPablo MaidClaudia Calle MontoroMaría A AlfaroBrian M RoldánAndrea B Gómez VaraPamela GiorgisRoberto A EzquerMaría G Crespo RochaCamila R Reyes GómezMaría Á CorreaOsvaldo L CerdaMarcos G RosemffetVirginia Carrizo AbarzaSantiago Catalan PelletMiguel PerandonesCecilia ReimundesYesica LongueiraGabriela TurkMaría F QuirogaNatalia LauferMaría C De La VegaGustavo CiteraGuillermo J Pons-EstelEmilce E SchneebergerPublished in: Arthritis care & research (2023)
In this RA cohort vaccinated with homologous and heterologous regimens against COVID-19, two out of ten patients did not develop IgG anti-SARS-CoV-2, 70% presented neutralizing activity and 65% specific T-cell response. The use of BBIBP-CorV was associated with deficient humoral and cellular response, while treatment with ABA and RTX resulted in an impaired IgG anti-SARS-CoV-2 formation and neutralizing activity. This article is protected by copyright. All rights reserved.